New diabetes drug tested in patients with liver problems
NCT ID NCT07193147
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a single dose of the experimental drug GZR4 injection behaves in people with mild, moderate, or severe liver impairment compared to those with normal liver function. The goal is to understand the drug's safety and how the body processes it. 36 adults with diabetes and varying liver health will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gan & Lee Pharmaceuticals Shandong Co., Ltd.
Linyi, Shandong, 276000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Text messages and nurses: a new strategy to tackle hypertension in tanzania?
- Could diabetes be silently damaging your hearing?
- Liver health and drug processing: a closer look at casdatifan
- Press play on better health: could recording doctor visits boost Self-Care in seniors?
- Putting Patients' priorities first: a new approach to ease the burden of multiple chronic illnesses
- A simple card game could transform diabetes care